Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.
What's in Store for Puma (PBYI) this Earnings Season?
by Zacks Equity Research
Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.
What's in the Cards for Celldex (CLDX) this Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?
by Zacks Equity Research
Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.
Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.
Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) is likely to see continued momentum in Vimizim and Kuvan sales backed by robust patient growth in Q2.
Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval
by Zacks Equity Research
Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.
Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.
Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock?
by Zacks Equity Research
Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately.
Key FDA Events to Watch Out for in Jul 2017
by Arpita Dutt
Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?
AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use
by Zacks Equity Research
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.
Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval
by Zacks Equity Research
Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.
Pfizer Provides Final Update on Phase II Talazoparib Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity
3 Hot Biotech Stocks to Buy in June
by Arpita Dutt
While drug pricing will remain a headline risk, here are a few biotech stocks that have performed well YTD and look well-positioned.
Puma Soaring After Neratinib FDA Panel Win, Time to Buy?
by Zacks Equity Research
Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.
Will Puma Biotechnology (PBYI) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Puma Biotechnology Inc (PBYI).
Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day.
Are Options Traders Betting on a Big Move in Puma (PBYI) Stock?
by Zacks Equity Research
Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately.
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now
by Zacks Equity Research
On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).
Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.
Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) reported a fourth-quarter 2016 loss of $2.04 per share (including the impact of stock-based compensation expenses), wider than both the Zacks Consensus Estimate of a loss of $2.02.